全文获取类型
收费全文 | 244435篇 |
免费 | 37837篇 |
国内免费 | 2730篇 |
专业分类
耳鼻咽喉 | 6095篇 |
儿科学 | 7733篇 |
妇产科学 | 4091篇 |
基础医学 | 15451篇 |
口腔科学 | 3187篇 |
临床医学 | 36487篇 |
内科学 | 65873篇 |
皮肤病学 | 8635篇 |
神经病学 | 24265篇 |
特种医学 | 10014篇 |
外国民族医学 | 3篇 |
外科学 | 55915篇 |
综合类 | 1309篇 |
现状与发展 | 72篇 |
一般理论 | 131篇 |
预防医学 | 14944篇 |
眼科学 | 5324篇 |
药学 | 7313篇 |
中国医学 | 111篇 |
肿瘤学 | 18049篇 |
出版年
2024年 | 731篇 |
2023年 | 5209篇 |
2022年 | 2050篇 |
2021年 | 5027篇 |
2020年 | 7157篇 |
2019年 | 4136篇 |
2018年 | 9680篇 |
2017年 | 8894篇 |
2016年 | 10093篇 |
2015年 | 10401篇 |
2014年 | 18500篇 |
2013年 | 19836篇 |
2012年 | 12749篇 |
2011年 | 13147篇 |
2010年 | 14558篇 |
2009年 | 17902篇 |
2008年 | 12627篇 |
2007年 | 11235篇 |
2006年 | 13399篇 |
2005年 | 10434篇 |
2004年 | 9570篇 |
2003年 | 7902篇 |
2002年 | 7655篇 |
2001年 | 4527篇 |
2000年 | 3462篇 |
1999年 | 3993篇 |
1998年 | 4725篇 |
1997年 | 4260篇 |
1996年 | 4005篇 |
1995年 | 3797篇 |
1994年 | 2476篇 |
1993年 | 2105篇 |
1992年 | 1771篇 |
1991年 | 1757篇 |
1990年 | 1356篇 |
1989年 | 1443篇 |
1988年 | 1268篇 |
1987年 | 1122篇 |
1986年 | 1106篇 |
1985年 | 990篇 |
1984年 | 836篇 |
1983年 | 770篇 |
1982年 | 847篇 |
1981年 | 681篇 |
1980年 | 579篇 |
1979年 | 404篇 |
1978年 | 455篇 |
1977年 | 501篇 |
1975年 | 344篇 |
1972年 | 349篇 |
排序方式: 共有10000条查询结果,搜索用时 18 毫秒
41.
42.
43.
William R. C. Knight Cara R. Baker Nyree Griffin Wahyu Wulaningsih Mark Kelly Andrew R. Davies James A. Gossage 《British journal of cancer》2021,124(10):1653
Background A high Mandard score implies a non-response to chemotherapy in oesophageal adenocarcinoma. However, some patients exhibit tumour volume reduction and a nodal response despite a high score. This study examines survival and recurrence patterns in these patients.Methods Clinicopathological factors were analysed using multivariable Cox regression assessing time to death and recurrence. Computed tomography-estimated tumour volume change was examined in a subgroup of consecutive patients.Results Five hundred and fifty-five patients were included. Median survival was 55 months (Mandard 1–3) and 21 months (Mandard 4 and 5). In the Mandard 4 and 5 group (332 patients), comparison between complete nodal responders and persistent nodal disease showed improved survival (90 vs 18 months), recurrence rates (locoregional 14.75 vs 28.74%, systemic 24.59 vs 48.42%) and circumferential resection margin positivity (22.95 vs 68.11%). Complete nodal response independently predicted improved survival (hazard ratio 0.34 (0.16–0.74). Post-chemotherapy tumour volume reduction was greater in patients with a complete nodal response (−16.3 vs −7.7 cm3, p = 0.033) with no significant difference between Mandard groups.Conclusion Patients with a complete nodal response to chemotherapy have significantly improved outcomes despite a poor Mandard score. High Mandard score does not correspond with a non-response to chemotherapy in all cases and patients with nodal downstaging may still benefit from adjuvant chemotherapy.Subject terms: Oesophageal cancer, Surgical oncology 相似文献
44.
Jamaal L. Benjamin MD PhD Rebecca Dennis DO Stacy White Jr MD David Munson MD Sudha A. Anupindi MD Maciej Piskunowicz MD Kassa Darge MD PhD Ami Gokli MD Misun Hwang MD 《Journal of ultrasound in medicine》2020,39(5):1031-1036
Bowel diseases of prematurity, including necrotizing enterocolitis, are dreaded ailments of neonates. Early diagnosis is difficult, with clinical and radiographic findings often inconclusive. We present a novel use of contrast-enhanced ultrasound in detection of pediatric bowel disease. Early identification of compromised blood flow or an at-risk bowel can be quantitatively detected and monitored. This ability has implications for guidance of emerging therapies, allowing targeting of inflammation. These findings represent an advancement in detection of bowel disease in neonates. 相似文献
45.
46.
Maaike van Gerwen MD Naomi Alpert MS Raja Flores MD Emanuela Taioli MD PhD 《American journal of industrial medicine》2020,63(2):115-120
The association between asbestos exposure, mainly in occupational settings, and malignant mesothelioma has been well established; this has prompted several countries to establish mesothelioma epidemiologic surveillance programs often at the request of national agencies. This review compares currently existing mesothelioma registries worldwide to develop a concept model for a US real-time case capture mesothelioma registry. Five countries were identified with a mesothelioma specific registry, including Italy, France, UK, Australia, and South Korea. All, except the UK, used interviews to collect exposure data. Linkage with the national death index was available or was in future plans for all registries. The registries have limited information on treatment, quality of life, and other patient-centered outcomes such as symptoms and pain management. To thoroughly collect exposure data, “real-time” enrollment is preferable; to maximize the capture of mesothelioma cases, optimal coverage, and a simplified consent process are needed. 相似文献
47.
48.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
49.
50.